MIA PaCa-2-hCLDN18.2
品系基本信息
驗證數(shù)據(jù)
Ⅰ.In vitro?Expression of MIA Paca-2-hCLDN18.2 cell line
Figure?1. hCLDN18.2 expression in MIA Paca-2 and MIA Paca-2-hCLDN18.2 cell lines
Ⅱ.Characterization of in vivo?growth kinetics
To test the take rates, and?the tumor growth characteristics of MIA Paca-2 -hCLDN18.2 cell line, cells?were subcutaneously inoculated into the M-NSG mice.
Figure?2. Tumor growth curve of MIA Paca-2-hCLDN18.2 xenograft model?model (n=5)
Figure?3. Body weight change of MIA Paca-2-hCLDN18.2 xenograft model?model (n=5)
Ⅲ.Expression of hCLDN18.2 protein in tumors
To verify the hCLDN18.2 protein expression, the tumors were dissected and separated for single cell suspension.
Figure?4. The expression of hCLDN18.2 in humanized modified tumors by FACS
你也可能感興趣
Cre-ERT2在無Tamoxifen誘導(dǎo)的情況下，在細(xì)胞質(zhì)內(nèi)處于無活性狀態(tài)；當(dāng)Tamoxifen誘導(dǎo)后，Tamoxifen的代謝產(chǎn)物4-OHT（雌激素類似物）與ERT結(jié)合，可使Cre-ERT2進核發(fā)揮Cre重組酶活性。
查看常見的基因工程小鼠可以分為兩種命名方式，包括基因定點修飾的小鼠命名，比如：敲除、敲入、點突變等等，和隨機轉(zhuǎn)基因的小鼠命名。
查看
